These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28400475)

  • 21. High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma.
    Coffey DG; Cowan AJ; DeGraaff B; Martins TJ; Curley N; Green DJ; Libby EN; Silbermann R; Chien S; Dai J; Morales A; Gooley TA; Warren EH; Becker PS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug response prediction in high-risk multiple myeloma.
    Vangsted AJ; Helm-Petersen S; Cowland JB; Jensen PB; Gimsing P; Barlogie B; Knudsen S
    Gene; 2018 Feb; 644():80-86. PubMed ID: 29122646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.
    Pintoffl JP; Weisel K; Schulze M; Maksimovic O; Claussen CD; Kramer U; Horger M
    J Ultrasound Med; 2013 Oct; 32(10):1777-88. PubMed ID: 24065259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutic avenues in myeloma: changing the treatment paradigm.
    Ghobrial J; Ghobrial IM; Mitsiades C; Leleu X; Hatjiharissi E; Moreau AS; Roccaro A; Schlossman R; Hideshima T; Anderson KC; Richardson P
    Oncology (Williston Park); 2007 Jun; 21(7):785-92; discussion 798-800. PubMed ID: 17722741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A look at treatment strategies for relapsed multiple myeloma.
    Cetani G; Boccadoro M; Oliva S
    Expert Rev Anticancer Ther; 2018 Aug; 18(8):735-750. PubMed ID: 29768064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current therapeutic strategies for multiple myeloma.
    Torimoto Y; Shindo M; Ikuta K; Kohgo Y
    Int J Clin Oncol; 2015 Jun; 20(3):423-30. PubMed ID: 25855312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel targeted therapies and combinations for the treatment of multiple myeloma.
    Agarwal A; Mahadevan D
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel investigational drugs active as single agents in multiple myeloma.
    D'Agostino M; Salvini M; Palumbo A; Larocca A; Gay F
    Expert Opin Investig Drugs; 2017 Jun; 26(6):699-711. PubMed ID: 28448171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
    Neri P; Bahlis NJ; Lonial S
    Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deacetylase inhibitors: an advance in myeloma therapy?
    Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
    Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalidomide and its derivatives: new promise for multiple myeloma.
    Weber D
    Cancer Control; 2003; 10(5):375-83. PubMed ID: 14581892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results.
    Horger M; Weisel K; Horger W; Mroue A; Fenchel M; Lichy M
    AJR Am J Roentgenol; 2011 Jun; 196(6):W790-5. PubMed ID: 21606271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 40. Overview of drug therapy for multiple myeloma.
    Saunders G
    J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.